Echtzeit-Aktienkurs Stemline Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der Stemline Therapeutics Inc. Aktie
Fundamentaldaten der Stemline Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2019 [USD] | 43,22 Mio. | -76,79 Mio. | -76,82 Mio. | -1,83 | - | - | - |
| 2018 [USD] | 0,50 Mio. | -85,02 Mio. | -85,02 Mio. | -3,00 | - | - | - |
| 2017 [USD] | 0,90 Mio. | -67,83 Mio. | -67,83 Mio. | -2,94 | - | - | - |
| 2016 [USD] | 1,04 Mio. | -38,33 Mio. | -38,30 Mio. | -2,15 | - | - | - |
| 2015 [USD] | 0,65 Mio. | -37,24 Mio. | -37,24 Mio. | -2,15 | - | - | - |
| 2014 [USD] | 0,34 Mio. | -28,83 Mio. | -28,83 Mio. | -2,23 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Stemline Therapeutics Inc. Aktie
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®� which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed the